Acuta Capital Partners’s Vaxcyte PCVX Stock Holding History

Acuta Capital Partners’s Portfolio PCVX Stock Details PCVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-45,000	Closed	-$3.68M	–	41
2024 Q4	$3.68M	Sell	45,000 -90,400	-67%	-$8.98M	3.71%	10
2024 Q3	$15.5M	Buy	135,400 +25,000	+23%	+$2.25M	12.53%	1
2024 Q2	$8.34M	Buy	110,400 +5,570	+5%	+$379K	7.02%	3
2024 Q1	$7.16M	Sell	104,830 -12,543	-11%	-$869K	4.65%	7
2023 Q4	$7.37M	Sell	117,373 -3,649	-3%	-$190K	4.15%	6
2023 Q3	$6.17M	Sell	121,022 -1,144	-0.9%	-$56.4K	4.13%	12
2023 Q2	$6.1M	Buy	122,166 +1,666	+1%	+$79K	4.13%	7
2023 Q1	$4.52M	Sell	120,500 -24,000	-17%	-$1.02M	3.33%	13
2022 Q4	$6.93M	Buy	144,500 +59,500	+70%	+$2.33M	4.26%	10
2022 Q3	$2.04M	Buy	+85,000	New	+$2.15M	0.88%	27

Other funds holding PCVX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Acuta Capital Partners's PCVX Position: Q1 2025 in Review

Acuta Capital Partners sold out of Vaxcyte (PCVX) in Q1 2025, closing a stake of 45,000 shares — an estimated $3.68M sold.

Acuta Capital Partners first reported a position in PCVX in Q3 2022 and held it in 10 quarters. The position peaked at $15.5M in Q3 2024. 315 funds tracked by Wall St. Rank hold PCVX as of Q1 2025.

Acuta Capital Partners reported no remaining Vaxcyte position as of Q1 2025 after selling out during the quarter.
Acuta Capital Partners sold 45,000 Vaxcyte shares in Q1 2025, an estimated $3.68M.
Acuta Capital Partners first reported a position in Vaxcyte in Q3 2022 and held it in 10 quarters.
Acuta Capital Partners's Vaxcyte position peaked at $15.5M in Q3 2024.
315 funds tracked by Wall St. Rank held Vaxcyte as of Q1 2025.

Based on Acuta Capital Partners's 13F filing for Q1 2025, filed 15 May 2025.